Brian Sylvester presentation covered FDA's Draft Guidance, providing the legal POV on insights not just for plant-based milks, but more broadly for understanding how FDA will approach the issue of naming of plant-based alternatives more generally. We will also consider this draft guidance in the broader context of consumer scrutiny and litigation and share our views on best practices for managing risk for a range of plant-based foods and alternative protein products.